ARTICLE | Clinical News
Mitoglitazone: Phase IIa data
September 23, 2013 7:00 AM UTC
A double-blind, U.S. Phase IIa trial in 29 non-diabetic patients aged 55-85 with mild AD showed that once-daily 150 mg MSDC-0160 met the primary endpoint of improving regional glucose metabolism level...